Paliperidonă Stada (Paliperidone)

Paliperidone, the active ingredient in Paliperidonă Stada, is an antipsychotic presented as a tablet for oral use. It is used to treat schizophrenia and schizoaffective disorder in adults.

GNH USA supplies Paliperidonă Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone is indicated for disorders that involve psychotic symptoms and mood instability. - Schizophrenia: Reduces frequency and severity of hallucinations, delusions and disorganized thinking. - Schizoaffective disorder: Improves mood symptoms and psychotic features. - Maintenance therapy: Helps prevent relapse of psychotic episodes after stabilization.

Paliperidone may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Akathisia: Restlessness and an urge to move constantly. - Weight gain: Increased appetite leading to modest weight increase. - Dry mouth: Reduced salivation causing a dry oral cavity. - Constipation: Slowed gastrointestinal motility. - Drowsiness: Generalised fatigue or sedation. - Elevated prolactin: Menstrual changes or galactorrhoea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: Involuntary, repetitive movements that may become permanent. - Seizures: Increased risk of convulsive episodes. - Cardiac arrhythmias: QT‑interval prolongation that can lead to serious rhythm disturbances. - Hyperglycaemia: Marked rise in blood glucose levels, especially in diabetic patients. - Severe hypotension: Sudden drop in blood pressure causing dizziness or fainting.

Paliperidone requires careful monitoring in several clinical situations. - Cardiovascular assessment: Baseline ECG and periodic monitoring for QT prolongation. - Metabolic monitoring: Check fasting glucose and lipid profile regularly. - Movement disorders: Observe for early signs of tardive dyskinesia or akathisia. - Pregnancy and lactation: Use only if the potential benefit outweighs risk to the fetus or infant. - Drug‑interaction vigilance: Review concomitant medications for CYP‑related effects. - Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture.

Paliperidone can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase paliperidone plasma levels and raise toxicity risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): May reduce paleneridise ").

Moderate Interactions (Monitor Closely): - Antihistamines, anticholinergics ant . -  "). d